Closing ADLR (Adolor) outperform
I think I called this one pretty well. I'm ending the pick now because I don't think the Pfizer deal is worth quite what the Street is giving. Momentum is still good so I may not be catching the top, but I'm trying not to be greedy. The 33CL230 trial data is now much more dangerous as is the Entereg PDUFA decision. I may short if the market cap goes over 300M without new positive catalysts.